MiRNAs in Gestational Diabetes Mellitus: Potential Mechanisms and Clinical Applications

Liu, Zhaonan; Jiang, Ying; Liu, Xuan-Qi; Chen, Cheng; Zhao, Baihui; Huang, He‐Feng; Luo, Qiong

doi:10.1155/2021/4632745

Cited by 19 publications

(23 citation statements)

References 150 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although our study could not confirm the clinical impact of universal GDM screening at 24–28 gestational weeks on stillbirth rates ≥24 gestational weeks in the general population, it did show an effect in the high‐risk population. It is speculated that early hyperglycemia, as may be present in women at high risk of GDM, may elicit epigenetic changes and influence fetal and placental programming, which might eventually lead to placental dysfunction 21,41 …”

Section: Discussionmentioning

confidence: 99%

“…It is speculated that early hyperglycemia, as may be present in women at high risk of GDM, may elicit epigenetic changes and influence fetal and placental programming, which might eventually lead to placental dysfunction. 21,41 In view of the wide spectrum of medical sequalae associated with GDM, universal GDM screening has been widely accepted as an important public health measure. However, more data are needed to verify the robust effects of GDM screening and total stillbirth reduction in early and late gestational weeks.…”

Section: One Example Of Such Data Is the Midlands And North Of Englandmentioning

confidence: 99%

See 1 more Smart Citation

Universal gestational diabetes screening and antepartum stillbirth rates in Austria—A population‐based study

Muin

Pfeifer

Helmer

et al. 2022

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Introduction Occult or untreated gestational diabetes (GDM) is a well‐known risk factor for adverse perinatal outcomes and may contribute to antepartum stillbirth. We assessed the impact of screening for GDM on the rate of antepartum stillbirths in non‐anomalous pregnancies by conducting a population‐based study in 974 889 women in Austria. Material and Methods Our database was derived from the Austrian Birth Registry. Inclusion criteria were singleton live births and antepartum stillbirths ≥24+0 gestational weeks, excluding fetal congenital malformations, terminations of pregnancy and women with pre‐existing type 1 or 2 diabetes. Main outcome measures were (a) overall stillbirth rates and (b) stillbirth rates in women at high risk of GDM (i.e., women with a body mass index ≥30 kg/m2, history of previous intrauterine fetal death, GDM, previous macrosomic offspring) before (2008–2010, “phase I”) and after (2011–2019, “phase II”) the national implementation of universal GDM screening with a 75 g oral glucose tolerance test in Austrian pregnant women by 2011. Results In total, 940 373 pregnancies were included between 2008 and 2019, of which 2579 resulted in intrauterine fetal deaths at 33.51 ± 5.10 gestational weeks. After implementation of the GDM screening, a statistically significant reduction in antepartum stillbirth rates among non‐anomalous singletons was observed only in women at high risk for GDM (4.10‰ [95% confidence interval (CI) 3.09–5.43] in phase I vs. 2.96‰ [95% CI 2.57–3.41] in phase II; p = 0.043) but not in the general population (2.76‰ [95% CI 2.55–2.99] in phase I vs. 2.74‰ [95% CI 2.62–2.86] in phase II; p = 0.845). The number needed to screen with the oral glucose tolerance test to subsequently prevent one case of (non‐anomalous) intrauterine fetal death was 880 in the high‐risk and 40 000 in the general population. Conclusions The implementation of a universal GDM screening program in Austria in 2011 has not led to any significant reduction in antenatal stillbirths among non‐anomalous singletons in the general population. More international data are needed to strengthen our findings.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: One Example Of Such Data Is the Midlands And North Of Englandmentioning

confidence: 99%

Universal gestational diabetes screening and antepartum stillbirth rates in Austria—A population‐based study

Muin

Pfeifer

Helmer

et al. 2022

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

“…Present trends in GDM investigations are gaining impetus where novel early gestation cellular markers are looked into with serious concern as they may cause serious and irreversible maternal or foetal complications post-childbirth. The miRNAs can be used as potential markers for the early screening of GDM [ 100 ]. A study revealed that the changes in the maternal metabolic processes might be directly linked with variations in the placental miRNA expression.…”

Section: Role Of Microrna In Gdmmentioning

confidence: 99%

Deep Insight of the Pathophysiology of Gestational Diabetes Mellitus

Sharma

Singh

Mahajan

et al. 2022

Cells

View full text Add to dashboard Cite

Diabetes mellitus is a severe metabolic disorder, which consistently requires medical care and self-management to restrict complications, such as obesity, kidney damage and cardiovascular diseases. The subtype gestational diabetes mellitus (GDM) occurs during pregnancy, which severely affects both the mother and the growing foetus. Obesity, uncontrolled weight gain and advanced gestational age are the prominent risk factors for GDM, which lead to high rate of perinatal mortality and morbidity. Zn in-depth understanding of the molecular mechanism involved in GDM will help researchers to design drugs for the optimal management of the condition without affecting the mother and foetus. This review article is focused on the molecular mechanism involved in the pathophysiology of GDM and the probable biomarkers, which can be helpful for the early diagnosis of the condition. The early diagnosis of the metabolic disorder, most preferably in first trimester of pregnancy, will lead to its effective long-term management, reducing foetal developmental complications and mortality along with safety measures for the mother.

show abstract

“…MicroRNAs are endogenous non-coding RNA molecules with a length of 19-22 nt (7). Many studies have shown that miRNAs are involved in the pathogenesis of GDM (8)(9)(10). miR-199a is differentially expressed specifically in patients with type 1 diabetes, type 2 diabetes and GDM (11,12).…”

Section: Introductionmentioning

confidence: 99%

miR-199a Is Upregulated in GDM Targeting the MeCP2-Trpc3 Pathway

et al. 2022

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM), the most common medical pregnancy complication, has become a growing problem. More and more studies have shown that microRNAs are closely related to metabolic processes. The purpose of this paper is to investigate the role of up-regulation of miR-199a-5p expression in GDM. We found that miR-199a-5p was significantly up-regulated in the placenta of GDM patients compared with normal pregnant women, and expressed in placental villi. miR-199a-5p can regulate the glucose pathway by inhibiting the expression of methyl CpG-binding protein 2 (MeCP2) and down-regulating canonical transient receptor potential 3 (Trpc3). This suggests that miR-199a-5p may regulate the glucose pathway by regulating methylation levels, leading to the occurrence of GDM.

show abstract

MiRNAs in Gestational Diabetes Mellitus: Potential Mechanisms and Clinical Applications

Cited by 19 publications

References 150 publications

Universal gestational diabetes screening and antepartum stillbirth rates in Austria—A population‐based study

Universal gestational diabetes screening and antepartum stillbirth rates in Austria—A population‐based study

Deep Insight of the Pathophysiology of Gestational Diabetes Mellitus

miR-199a Is Upregulated in GDM Targeting the MeCP2-Trpc3 Pathway

Contact Info

Product

Resources

About